TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Non-inferiority of PRO-122 Ophthalmic Solution vs KRYTANTEK Ofteno® in Glaucoma or Ocular Hypertension (CONFORTK)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* male or female.~* obtained in the external consultation.~* With diagnosis primary of open-angle glaucoma and / or hypertension classified as mild, moderate or severe glaucomatous damage, users of Krytantek Ofteno® at least two months prior to inclusion and under control of the target IOP.~* informed consent.~Exclusion Criteria:~General Criteria~1. Subjects with topical or systemic medication that interferes decisively in the results of the study. (Such as topical immunomodulators, lacrimal point tamponade, corticosteroids, ocular hypotensives other than those listed above, artificial tears with preservative).~2. Subjects (female) with an active sex life who are not using a contraceptive method.~3. Female Subjects in pregnancy or breastfeeding.~4. Female subjects with positive urine pregnancy test.~5. Positive drug addiction (verbal interrogation).~6. Subjects who have participated in any clinical research study in the last 40 days.~7. Legally or mentally disabled subjects to give informed consent for their participation in this study.~8. Subjects who can not comply with the appointments or with all the requirements of the protocol.~Ophthalmologic criteria~1. Subject with only one eye with vision.~2. Subjects with visual capacity 20/200 or worse.~3. Subjects with a narrow-angle history without treatment, with or without total or partial closure of the angle in either eye.~4. Subjects with corneal abnormalities that prevent applanation tonometry.~5. Subjects with ocular surgery or ocular trauma 6 months prior to inclusion.~6. Any ocular laser surgery 3 months prior.~7. Any uncontrolled or progressive retinal disease.~8. Inflammatory diseases of any kind.~9. Contact lens wearers.~10. Subjects with a history of hypersensitivity to any of the ingredients of the research product or its analogues.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A (Type: OTHER): In group A, therapy with Krytantek Ofteno® will be continued for 30 days, in which the subject will be retested and switched to a PRO-122 solution which will be used for 30 days until the 60th day, The final visit.
- Group B (Type: OTHER): In group B, therapy with Krytantek Ofteno® will be suspended and changes for PRO-122 for 30 days, in which the subject will be retested and later switched to Krytantek Ofteno® solution which will be used for 30 days until the 60th day, The final visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Unloader Bracing in Clinical Outcome and Cartilage Physiology Following Microfracture of Chondral Defects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* isolated chondral defect of medial or lateral femoral condyle 2cm squared or less~* age 15-40~* neutral knee alignment~Exclusion Criteria:~* prior cartilage procedures performed in the same knee~* other significant knee pathology including meniscus tears, ligament tears or inflammatory arthritis

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Unloader Bracing (Type: EXPERIMENTAL): This group will be randomly selected and assigned to wear an unloader brace post-operatively during the study period.
- Non-Bracing Arm (Type: ACTIVE_COMPARATOR): This group will be randomly selected and assigned to wear no brace post-operatively.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Hepatitis B Virus Vertical Transmission by Serovaccination and Tenofovir During Pregnancy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* pregnant women~* positive for HBs Ag~* HBV DNA above 100,000 I.U/mL~Exclusion Criteria:~* HIV co-infection~* HDV co-infection~* requiring, according to the physician's decision, a treatment for herself and not only to prevent HBV MTC transmission

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- tenofovir (Type: OTHER): tenofovir DF one pill (245 mg) per day from week 28 of pregnancy to week 12 after birth

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Definite or probable CIDP according to the European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) criteria 2010.~* An IVIG treatment during the last 8 weeks prior to enrollment.~* Age ≥18 years.~* Written informed consent for study participation obtained before undergoing any study-specific procedures.~Exclusion Criteria:~* Any polyneuropathy of other causes~* Any other disease (mainly neurological or chronic orthopedic) that has caused neurological symptoms or may interfere with treatment or outcome assessments~* Severe diseases and conditions that are likely to interfere with evaluation of the study product or satisfactory conduct of the study~* History of thrombotic episodes within the 2 years prior to enrolment~* Known allergic or other severe reactions to blood products including intolerability to previous IVIG

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IgPro20 low dose (Type: EXPERIMENTAL): None
- IgPro20 high dose (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Methodology Study in Healthy Subjects to Evaluate the Effect of AZD8309 After Nasal Administration of Lipopolysaccharide (LPS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy men or healthy, permanently sterilized, women aged 18 to 50 years inclusive, non-smokers or ex-smokers, Body Mass Index 18 to 30 kg/m2 and minimum body weight of 50 kg~* Blood neutrophil count above 2.2x10\^9/L~Exclusion Criteria:~* Clinical relevant disease and/or abnormality

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): AZD8309
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Colchicine to Treat Acute Pericarditis and Prevent Recurrences

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with acute pericarditis (index attack)~* Age≥ 18 years~* Informed consent~Exclusion Criteria:~* Suspected neoplastic, tuberculous, or purulent etiology~* Known severe liver disease and/or elevated transaminases \>1.5 times the upper limit of normality~* Serum creatinine \>2.5 mg/dl~* Serum creatine kinase (CK) over the upper limit of normality or known myopathy~* Known gastrointestinal or blood disease~* Pregnant or lactating women or women not protected by a contraception method~* Known hypersensibility to colchicine~* Treatment with colchicine at enrolment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Conventional therapy plus placebo
- Colchicine (Type: ACTIVE_COMPARATOR): Conventional therapy plus colchicine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of a New Catheter Material for Intermittent Catheterization

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of informed consent~* Males, aged 18 years and over~* Maintained urethra sensibility~* Practice intermittent self-catheterization at least 2 times daily~* Using catheters in the length of 40 cm and size charrière (Ch) 12 or Ch 14~* Experienced practitioners of intermittent self-catheterization defined as a minimum of three months on therapy~* Experience of using LoFric catheter within the last 12 months prior to study entry~* Adults able to read, write and understand information given to them regarding the study~Exclusion Criteria:~* Ongoing, symptomatic urinary tract infection (UTI) at enrolment as judged by investigator~* Known urethral stricture at enrolment as judged by investigator~* Involvement in the planning and/or conduct of the study (applies to both Astra Tech staff or staff at the study site)~* Previous enrolment or randomisation of treatment in the present study

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LoFric POBE 2.0 - PVC (Type: EXPERIMENTAL): First period (7 days) use of LoFric POBE 2.0 followed by second period (7 days) use of LoFric PVC
- LoFric PVC - POBE 2.0 (Type: EXPERIMENTAL): First period (7 days) use of LoFric PVC followed by second period (7 days) use of LoFric POBE 2.0.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treating Acutely Agitated Patients With Asenapine Sublingual Tablets

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients will be between the ages of 18 and 65~* Be acutely agitated as determined by a total score of ≧ 14 on the PANSS-EC and at least one individual item score of ≧ 4~* Patients must have the capacity to provide informed consent, and such consent will be obtained prior to participation~Exclusion Criteria:~* Patient is knowingly pregnant~* Patient is less than 18 or greater than 65 years old~* Patient had a past adverse or allergic response to Asenapine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Asenapine (Type: EXPERIMENTAL): This group received 10mg asenapine sl x 1 dose
- Placebo (Type: PLACEBO_COMPARATOR): This group received placebo sl x 1 dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Testosterone and Weight Loss

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* BMI \>30~Exclusion Criteria:~* contraindications to testosterone therapy

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- testosterone (Type: ACTIVE_COMPARATOR): against placebo
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have a histologically confirmed CD20 +ve follicular lymphoma grades I to IIIa.~* Patients with at least one of the following symptoms requiring initiation of treatment: (as outlined by the modified BNLI/GELF criteria below)~  * Nodal mass \> 7cm in its greater diameter~ * B symptoms~ * Elevated serum LDH or beta2-microglobulin~ * involvement of at least 3 nodal sites (each with a diameter \> 3 cm)~ * symptomatic splenic enlargement~ * compressive syndrome~* Patients must have an ECOG performance status less than or equal to 2 and an anticipated survival of at least 6 months.~* Patients must have an absolute granulocyte count of above 1,500/mm3, and a platelet count of above 100,000/mm3 post 4 weeks of unlabelled Rituximab. A hemoglobin \>= 8.0 g/dl~* Patients must have adequate renal function (defined as calculated creatinine clearance \> 30 ml/mn), hepatic function (defined as total bilirubin \<1.5 times upper limit of normal), and hepatic transaminases (defined as AST \<5 times upper limit of normal)~* Patients must have given informed consent prior to study entry.~Exclusion Criteria:~* Patients with a mean of \>20% of the intratrabecular marrow space involved with lymphoma on bone marrow biopsy following induction Rituximab therapy.~* Transformed follicular lymphoma and discordant lymphoma~* Patients with active obstructive hydronephrosis.~* Patients with initial disease bulk greater than 10cm.~* Patients with evidence of active infection requiring i.v. antibiotics at the time of study entry.~* Patients with congestive heart failure stage III or IV of NYHA classification, myocardial infraction or unstable angina within 6 months or other serious illness that would preclude evaluation.~* Patients with left VEF \< 40%~* Patients with large pleural or peritoneal effusions.~* Patients with known HIV infection or active HBV (HbsAg positivity) or HCV infection.~* Known Hypersensitivity to murine antibodies or proteins~* Patients who are pregnant or breast-feeding. Male and female patients must agree to use effective contraception for 12 months following 90Y-ibritumomab tiuxetan antibody therapy.~* Patients with prior malignancy other than lymphoma, except for adequately-treated skin cancer, cervical cancer in situ, or other cancer for which the patient has been disease-free for 5 years.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fractionated Initial Zevalin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized, Open-label, Single Dose, Parallel Study to Evaluate the Pharmacokinetics Dose Proportionality of GLA5PR GLARS-NF1 Tablet in Healthy Male Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* 19\~45 years old, Healthy Adult Male Subject~* 17.5\~30.5kg/m2(BMI) and ≥ 40kg(Body Weight)~Exclusion Criteria:~* SBP ≥ 140mmHg or DBP ≥ 90mmHg

- Gender: MALE
- Minimum Age: 19 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- GLA5PR GLARS-NF1 tablet 150mg (Type: EXPERIMENTAL): GLA5PR GLARS-NF1 tablet 150mg/day(Pregabalin 150mg once a day, after meal)
- GLA5PR GLARS-NF1 tablet 300mg (Type: EXPERIMENTAL): GLA5PR GLARS-NF1 tablet 300mg/day(Pregabalin 300mg once a day, after meal)
- GLA5PR GLARS-NF1 tablet 450mg (Type: EXPERIMENTAL): GLA5PR GLARS-NF1 tablet 450mg/day(Pregabalin 150mg 1 tablet and Pregabalin 300mg 1 tablet, 1 times a day, after meal)
- GLA5PR GLARS-NF1 tablet 600mg (Type: EXPERIMENTAL): GLA5PR GLARS-NF1 tablet 600mg/day(Pregabalin 300mg, 2 tablets 1 times a day, after meal)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Late Phase 2 Study of OPC-12759 Ophthalmic Suspension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Outpatient~2. Subjective complaint of dry eye that has been present for minimum 20 months~3. Ocular discomfort severity is moderate to severe~4. Corneal - conjunctival damage is moderate to severe~5. Unanesthetized Schirmer's test score of 5mm/5minutes or less~6. Best corrected visual acuity of 0.2 or better in both eyes~Exclusion Criteria:~1. Presence of anterior segment disease or disorder other than that associated with keratoconjunctivitis sicca~2. Ocular hypertension patient or glaucoma patient with ophthalmic solution~3. Anticipated use of any topically-instilled ocular medications or patients who cannot discontinue the use during the study~4. Anticipated use of contact lens during the study~5. Patient with punctal plug~6. Any history of ocular surgery within 12 months~7. Female patients who are pregnant, possibly pregnant or breast feeding~8. Known hypersensitivity to any component of the study drug or procedural medications~9. Receipt of any investigational product within 4 months

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): 0% OPC-12759 ophthalmic suspension received one drop to both eyes four times a day for 4 weeks.
- 1% OPC-12759 ophthalmic suspension (Type: EXPERIMENTAL): 1% OPC-12759 ophthalmic suspension received one drop to both eyes four times a day for 4 weeks.
- 2% OPC-12759 ophthalmic suspension (Type: EXPERIMENTAL): 2% OPC-12759 ophthalmic suspension received one drop to both eyes four times a day for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Pharmacokinetic, Pharmacodynamic, Safety and Efficacy Study of Three Anti-CD20 Monoclonal Antibodies in Patients With Moderate to Severe Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients, 18 to 65 years of age~2. Diagnosis of RA, according to ACR criteria (1987), of at least 6 months duration~3. At randomization, tender joint count ≥ 6 and swollen joint count ≥ 6~4. Evidence of at least moderate disease activity~5. Patients receiving oral or parenteral MTX with a dose of 15 to 25 mg per week when given alone or 10 to 25 mg per week in combination with additional non-biologic DMARD(s) for at least 6 months and on stable dose for at least 3 months~6. Patients must be on a stable dose of folic acid or equivalent (≥5 mg per week)~7. Chest X-ray not suggestive of any lung infections including pulmonary tuberculosis (TB)~8. Contraception required per protocol~Exclusion Criteria:~1. Prior therapy with~   * Rituximab, abatacept, tocilizumab, anakinra or an agent/antibody targeting CD20, CD19 or B cells~  * Tumor necrosis factor (TNF) alfa antagonists or other biologic DMARDs~   Other prior or concurrent therapies may also be excluded~2. Any clinically relevant abnormality detected on screening history, physical examination, clinical laboratory, chest X-ray, or electrocardiogram (ECG), other than values consistent with RA~3. Evidence of active, suspected or inadequately treated TB~4. Positive serological test for hepatitis C virus antibodies, hepatitis B surface antigen, hepatitis B core antibody, or human immunodeficiency virus~5. History of cardiovascular disease, history of stroke, or uncontrolled hypertension~6. History of lymphoproliferative disease or organ allograft~7. History of cancer (except for in situ cancer, excised, or limited stage, curatively treated cancer with no sign of disease for \>5 years)~8. History of allergy (medication history) to any of the compounds used in the study~9. Pregnant or lactating women or women planning to become pregnant during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- DRL_RI (Type: EXPERIMENTAL): None
- Rituxan (Type: ACTIVE_COMPARATOR): None
- MabThera (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete